NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and G…
Medical - Instruments & Supplies
JE, Saint Helier [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 8.36 | 6.26 | 5.78 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 95.33 | -3.66 | -78.22 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -1.13 | 3.35 | 3.39 | |
| Cash | -4.70 | 8.11 | 8.51 | |
| Capex | -72.31 | -0.11 | -0.06 | |
| Free Cash Flow | -102.27 | -0.40 | -0.20 | |
| Revenue | 3.25 | 1.29 | 1.25 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.01 | 0.76 | 0.76 | |
| Operating Margin | 22.45 | -0.30 | -0.39 | |
| ROA | 15.86 | -0.03 | -0.04 | |
| ROE | 16.95 | -0.11 | -0.13 | |
| ROIC | 24.47 | -0.05 | -0.07 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of NVCR is permitted for members.
5
Growth
The "Growth Entry" for the Focus of NVCR is permitted for members.
6
Leverage & Liquidity